Abstract:Background: The overall objective of the present study is to extend our understanding of the clinical phenotype and underlying mechanism of a newly discovered cardiac arrhythmia syndrome through a multicenter study. Gain-of-function mutations in the cardiac Ca 2+ release channel (RyR2 [ryanodine receptor 2]) cause catecholaminergic polymorphic ventricular tachycardia, whereas loss-of-function RyR2 mutations are linked to a new cardiac arrhythmia disorder termed Ca 2+ -release deficiency syndrome (CRDS). Catecholaminergic polymorphic ventricular tachycardia is an inherited arrhythmia disorder characterized by stress-induced bidirectional and polymorphic ventricular tachyarrhythmias and is routinely diagnosed by using exercise stress testing. Conversely, RyR2-CRDS is characterized by ventricular arrhythmias and sudden cardiac death but a negative exercise stress testing for catecholaminergic polymorphic ventricular tachycardia. There are currently no clinical diagnostic tests for CRDS and affected patients may manifest with sudden cardiac death as their first symptom. In the absence of effective clinical diagnostic tools, in vitro functional characterization of associated RyR2 mutations provides an alternative means to identify potential cases of CRDS. Methods: We searched for patients presenting with phenotypes compatible with CRDS that have RyR2 mutations and performed in vitro functional characterization. Results: We found that 3 novel (G570D, R4147K, and A4203V) and 2 previously reported (M4109R and A4204V) RyR2 mutations associated with CRDS phenotypes markedly reduced caffeine-induced Ca 2+ release and store overload-induced Ca 2+ release. We also characterized 2 additional loss-of-function RyR2 mutations previously reported (Q3925E and L4769S) that are located in the central and channel pore-forming domains critical for Ca 2+ activation and channel gating. Q3925E was identified through postmortem genetic testing in an individual who died suddenly, while L4769S is a variant of uncertain significance reported in ClinVar, suggesting that RyR2 CRDS may be under detected. Conclusions: These findings provide further support for the existence of an emerging RyR2 loss-of-function associated arrhythmia syndrome (CRDS) and shed new insights into the disease mechanism.

A gain of function ryanodine receptor 2 mutation (R1760W-RyR2) in catecholaminergic polymorphic ventricular tachycardia

Characterization of a Novel Mutation in the Cardiac Ryanodine Receptor That Results in Catecholaminergic Polymorphic Ventricular Tachycardia

Loss of Luminal Ca 2+ Activation in the Cardiac Ryanodine Receptor is Associated with Ventricular Fibrillation and Sudden Death

RyR 2 Mutations Linked to Ventricular Tachycardia and Sudden Death Reduce the Threshold for Store-Overload-induced Ca 2 Release ( SOICR )

Enhanced Store Overload–Induced Ca 2+ Release and Channel Sensitivity to Luminal Ca 2+ Activation Are Common Defects of RyR2 Mutations Linked to Ventricular Tachycardia and Sudden Death

Enhanced Basal Activity of a Cardiac Ca2+ Release Channel (ryanodine Receptor) Mutant Associated with Ventricular Tachycardia and Sudden Death.

Functional Consequence of Protein Kinase A-dependent Phosphorylation of the Cardiac Ryanodine Receptor: Sensitization of Store Overload-Induced Ca2+ Release.

Endoplasmic Reticulum Ca2+ Measurements Reveal That the Cardiac Ryanodine Receptor Mutations Linked to Cardiac Arrhythmia and Sudden Death Alter the Threshold for Store-Overload-induced Ca2+ Release.

Arrhythmogenesis in a catecholaminergic polymorphic ventricular tachycardia mutation that depresses ryanodine receptor function

CPVT-associated Cardiac Ryanodine Receptor Mutation G357S with Reduced Penetrance Impairs Ca2+ Release Termination and Diminishes Protein Expression

Identification of Loss-of-function RyR2 Mutations Associated with Idiopathic Ventricular Fibrillation and Sudden Death

A De Novo Heterozygous Cardiac Ryanodine Receptor Gene (RYR2) Mutation in a Catecholaminergic Polymorphic Ventricular Tachycardia Patient

Characterization of N-terminal RYR2 variants outside CPVT1 hotspot regions using patient iPSCs reveal pathogenesis and therapeutic potential

Human RyR2 (ryanodine Receptor 2) Loss-of-Function Mutations

Novel RyR2 Mutation (G3118R) is Associated with Autosomal Recessive Ventricular Fibrillation and Sudden Death: Clinical, Functional, and Computational Analysis

Impaired Binding to Junctophilin2 and Nanostructural Alteration in CPVT Mutation

A novel RyR2 mutation associated with co -morbid catecholaminergic polymorphic ventricular tachycardia (CPVT) and benign epilepsy with centrotemporal spikes (BECTS)

Genetic Inhibition of Mitochondrial Permeability Transition Pore Exacerbates Ryanodine Receptor 2 Dysfunction in Arrhythmic Disease

Molecular characterization of the calcium release channel deficiency syndrome.

Structure-activity optimization of ryanodine receptor modulators for the treatment of catecholaminergic polymorphic ventricular tachycardia

The RyR2-P2328S Mutation Downregulates Nav1.5 Producing Arrhythmic Substrate in Murine Ventricles